Literature DB >> 17595794

Aspiration occurence during chemoradiation for head and neck cancer.

Nam P Nguyen1, Herbert J Smith, Suresh Dutta, Alan Alfieri, Debra North, Phuc D Nguyen, Howard Lee, Tomas Martinez, Claire Lemanski, Adir Ludin, Ly M Nguyen, Sabah Sallah.   

Abstract

AIM: To assess the risk of developing aspiration during chemoradiation for head and neck cancer. PATIENTS AND METHODS: A retrospective review of 114 patients who underwent concurrent chemoradiation for locally advanced head and neck cancer was undertaken. Patients were determined as having aspiration if they had pneumonia on chest-X-ray (CXR) and/or had documented aspiration on the modified barium swallow (MBS) during their treatment.
RESULTS: Fifteen patients (13%) developed aspiration during chemoradiation. Twelve patients (10%) had aspiration demonstrated on CXR alone (9 patients) or combined with MBS (3 patients). Three patients (3%) had aspiration on MBS alone. Three of the six patients with aspiration observed on MBS had normal swallowing on their pretreatment MBS. All 15 patients had severe mucositis and neutropenia at the time of the aspiration. Despite broad-spectrum antibiotics and supportive care, six patients (5%) died.
CONCLUSION: Aspiration may develop during chemoradiation for head and neck cancer because of radiation-induced altered swallow.

Entities:  

Mesh:

Year:  2007        PMID: 17595794

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

1.  Tolerance of Chemoradiation in Advanced Head and Neck Cancers: Comparison Between Inpatients and Outpatients.

Authors:  Virender Suhag; B S Sunita; Pankaj Vats; N Chakravarty; Tejas Pandya; Nishant Lohia
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2017-10-06

2.  A randomized prospective study of rehabilitation therapy in the treatment of radiation-induced dysphagia and trismus.

Authors:  Y Tang; Q Shen; Y Wang; K Lu; Y Wang; Y Peng
Journal:  Strahlenther Onkol       Date:  2010-12-10       Impact factor: 3.621

3.  Aspiration pneumonia after concurrent chemoradiotherapy for head and neck cancer.

Authors:  Beibei Xu; Isabel J Boero; Lindsay Hwang; Quynh-Thu Le; Vitali Moiseenko; Parag R Sanghvi; Ezra E W Cohen; Loren K Mell; James D Murphy
Journal:  Cancer       Date:  2014-12-23       Impact factor: 6.860

4.  Respiratory-swallow phase patterns and their relationship to swallowing impairment in patients treated for oropharyngeal cancer.

Authors:  Martin B Brodsky; David H McFarland; Thomas S Dozier; Julie Blair; Christopher Ayers; Yvonne Michel; M Boyd Gillespie; Terry A Day; Bonnie Martin-Harris
Journal:  Head Neck       Date:  2010-04       Impact factor: 3.147

5.  Aspiration pneumonia after chemo-intensity-modulated radiation therapy of oropharyngeal carcinoma and its clinical and dysphagia-related predictors.

Authors:  Klaudia U Hunter; Oliver E Lee; Teresa H Lyden; Marc J Haxer; Felix Y Feng; Mathew Schipper; Francis Worden; Mark E Prince; Scott A McLean; Gregory T Wolf; Carol R Bradford; Douglas B Chepeha; Avraham Eisbruch
Journal:  Head Neck       Date:  2013-06-01       Impact factor: 3.147

6.  Risk factors for aspiration pneumonia after definitive chemoradiotherapy or bio-radiotherapy for locally advanced head and neck cancer: a monocentric case control study.

Authors:  Sadayuki Kawai; Tomoya Yokota; Yusuke Onozawa; Satoshi Hamauchi; Akira Fukutomi; Hirofumi Ogawa; Tsuyoshi Onoe; Tetsuro Onitsuka; Takashi Yurikusa; Akiko Todaka; Takahiro Tsushima; Yukio Yoshida; Yosuke Kito; Keita Mori; Hirofumi Yasui
Journal:  BMC Cancer       Date:  2017-01-17       Impact factor: 4.430

Review 7.  Feasibility of intensity-modulated and image-guided radiotherapy for functional organ preservation in locally advanced laryngeal cancer.

Authors:  Nam P Nguyen; Alexander Chi; Michael Betz; Fabio Almeida; Paul Vos; Rick Davis; Benjamin Slane; Misty Ceizyk; Dave Abraham; Lexie Smith-Raymond; Michelle Stevie; Siyoung Jang; Steven Gelumbauskas; Vincent Vinh-Hung
Journal:  PLoS One       Date:  2012-08-20       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.